Genscript Biotech Corporation - Asset Resilience Ratio

Latest as of December 2025: 13.79%

Genscript Biotech Corporation (G51) has an Asset Resilience Ratio of 13.79% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€669.50 Million

≈ $782.72 Million USD Cash + Short-term Investments

Total Assets

€4.85 Billion

≈ $5.67 Billion USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Genscript Biotech Corporation's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Genscript Biotech Corporation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Genscript Biotech Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see G51 market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€669.50 Million	13.79%
Total Liquid Assets	€669.50 Million	13.79%

Asset Resilience Insights

Moderate Liquidity: Genscript Biotech Corporation has 13.79% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Genscript Biotech Corporation Industry Peers by Asset Resilience Ratio

Compare Genscript Biotech Corporation's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Akero Therapeutics Inc NASDAQ:AKRO	Biotechnology	55.87%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Zealand Pharma A/S CO:ZEAL	Biotechnology	63.98%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Immunitybio Inc NASDAQ:IBRX	Biotechnology	38.07%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Annual Asset Resilience Ratio for Genscript Biotech Corporation (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Genscript Biotech Corporation.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	13.79%	€669.50 Million ≈ $782.72 Million	€4.85 Billion ≈ $5.67 Billion	+4.53pp
2024-12-31	9.27%	€489.19 Million ≈ $571.92 Million	€5.28 Billion ≈ $6.17 Billion	-4.95pp
2023-12-31	14.22%	€481.65 Million ≈ $563.10 Million	€3.39 Billion ≈ $3.96 Billion	-3.03pp
2022-12-31	17.25%	€439.33 Million ≈ $513.62 Million	€2.55 Billion ≈ $2.98 Billion	+7.30pp
2021-12-31	9.95%	€222.23 Million ≈ $259.81 Million	€2.23 Billion ≈ $2.61 Billion	+0.13pp
2020-12-31	9.82%	€142.11 Million ≈ $166.14 Million	€1.45 Billion ≈ $1.69 Billion	-9.76pp
2019-12-31	19.58%	€174.13 Million ≈ $203.57 Million	€889.41 Million ≈ $1.04 Billion	+11.94pp
2018-12-31	7.64%	€70.06 Million ≈ $81.90 Million	€916.98 Million ≈ $1.07 Billion	+7.03pp
2017-12-31	0.61%	€3.09 Million ≈ $3.61 Million	€504.26 Million ≈ $589.54 Million	--

pp = percentage points

About Genscript Biotech Corporation

F:G51 Germany Biotechnology

Market Cap

$5.01 Billion

€4.28 Billion EUR

Market Cap Rank

#4518 Global

#784 in Germany

Share Price

€1.96

Change (1 day)

+4.81%

52-Week Range

€1.14 - €2.04

All Time High

€4.62